Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 9
Submit an article Journal homepage
821
Views
16
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Phase III, randomized study of ofatumumab versus physicians’ choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia

Anders ÖsterborgDepartment of Hematology, Karolinska University Hospital, Stockholm, Sweden; Correspondence[email protected]
,
Miklós UdvardyInstitute of Internal Medicine Building B, Haemopoetic Transplantation Centre, DEOEC (Debreceni Egyetem Orvos És Egészségtudományi Centrum), Debrecen, Hungary;
,
Andrey ZaritskeyCenter of Heart Blood and Endocrinology, St Petersburg, Russia;
,
Per-Ola AnderssonSödra Älvsborgs Sjukhus, Borås, Sweden;
,
Sebastian GrosickiDepartment of Cancer Prevention, Faculty of Public Health, Silesian Medical University, Katowice, Poland;
,
Grzegorz MazurWroclaw Medical University, Wroclaw, Poland;
,
Polina KaplanDnipropetrovsk City Clinical Hospital No. 4, Dnipropetrovsk, Ukraine;
,
Michael SteurerInnsbruck Medical University, Innsbruck, Austria;
,
Anna SchuhChurchill Hospital, Oxford, UK;
,
Marco MontilloOspedale Niguarda Ca’Granda, Milan, Italy;
,
Iryna KryachokNational Cancer Institute, Kiev, Ukraine;
,
Jan Moritz MiddekeUniversitaetsklinikum Carl Gustav Carus, Dresden, Germany;
,
Yaroslav KulyabaMakiivka City Hospital #2 of Donetsk Region, Makiivka, Ukraine;
,
Grygoriy RekhtmanKhmelnytskyi Regional Hospital, Khmelnytskyi, Ukraine;
,
Michele GorczycaPfizer Inc, Collegeville, PA, USA;
,
Siobhan DalyNovartis Pharmaceuticals, Dublin, Ireland;
,
Chai-Ni ChangNovartis Pharmaceuticals, Research Triangle Park, NC, USA;
,
Steen LisbyGenmab, Copenhagen, Denmark;
&
Ira GuptaNovartis Pharmaceuticals, Wayne, PA, USA
 show all
Pages 2037-2046 | Received 01 Sep 2015, Accepted 16 Nov 2015, Published online: 19 Jan 2016

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Jenny J Feng & Daniel Ontaneda. (2017) Treating primary-progressive multiple sclerosis: potential of ocrelizumab and review of B-cell therapies. Degenerative Neurological and Neuromuscular Disease 7, pages 31-45.
Read now
Yougen Wu, Yang Wang, Yuting Gu, Ju Xia, Xiaoyang Kong, Qingqing Qian & Yang Hong. (2017) Safety and efficacy of Ofatumumab in chronic lymphocytic leukemia: a systematic review and meta-analysis. Hematology 22:10, pages 578-584.
Read now

Articles from other publishers (14)

Zeineb Zian, Abubakar Umar Anka, Hamisu Abdullahi, Emna Bouallegui, Shayan Maleknia & Gholamreza Azizi. 2024. Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal. Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal 273 298 .
Muhammad Hossein Ashoub, Amirreza Naseri, Parisa Mohammadi & Masoud Mohammadi. (2023) Ofatumumab regimens in chronic lymphocytic leukemia: a meta-analysis. Annals of Hematology 102:6, pages 1301-1306.
Crossref
Merve BABAÇ, Meliha EKİNCİ & Derya İLEM-ÖZDEMİR. (2023) KANSER TANISI VE TEDAVİSİNDE KULLANILAN MONOKLONAL ANTİKORLARMONOCLONAL ANTIBODIES USED IN CANCER DIAGNOSIS AND TREATMENT. Ankara Universitesi Eczacilik Fakultesi Dergisi 47:1, pages 2-2.
Crossref
Stephanos Vassilopoulos, Fadi Shehadeh, Markos Kalligeros, Quynh-Lam Tran, Fred Schiffman & Eleftherios Mylonakis. (2022) Targeted therapies in CLL/SLL and the cumulative incidence of infection: A systematic review and meta-analysis. Frontiers in Pharmacology 13.
Crossref
Kenji Kufukihara. (2021) Anti‐B cell therapies in multiple sclerosis. Clinical and Experimental Neuroimmunology 12:4, pages 228-237.
Crossref
MAXIMILIAN SALCHER‐KONRAD, HUSEYIN NACI & COURTNEY DAVIS. (2020) Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States. The Milbank Quarterly 98:4, pages 1219-1256.
Crossref
Despoina Florou, Maria Katsara, Jack Feehan, Efthimios Dardiotis & Vasso Apostolopoulos. (2020) Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab. Brain Sciences 10:10, pages 758.
Crossref
Udvardy Miklos, Vladimir Strugov, Catharina Lewerin, Sebastian Grosicki, Grzegorz Mazur, Michael Steurer, Marco Montillo, Irina Kryachok, Jan M. Middeke, Grygoriy Rekhtman, Tommaso Stefanelli, Ghislaine Vincent, Sameera Govindaraju & Anders Österborg. (2020) Five‐year survival follow‐up of a phase III randomised trial comparing ofatumumab versus physicians' choice for bulky fludarabine‐refractory chronic lymphocytic leukaemia: a short report . British Journal of Haematology 189:4, pages 689-693.
Crossref
Robert F. Graziano & John J. Engelhardt. 2019. Fc Mediated Activity of Antibodies. Fc Mediated Activity of Antibodies 13 34 .
Marie Viala, Marie Vinches, Marie Alexandre, Caroline Mollevi, Anna Durigova, Nadia Hayaoui, Krisztian Homicsko, Alice Cuenant, Céline Gongora, Luca Gianni & Diego Tosi. (2018) Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection. British Journal of Cancer 118:5, pages 679-697.
Crossref
Zar Ni Soe & David Allsup. (2017) The use of ofatumumab in the treatment of B-cell malignancies. Future Oncology 13:29, pages 2611-2628.
Crossref
Lotta Hansson, Anna Asklid, Joris Diels, Sandra Eketorp-Sylvan, Johanna Repits, Frans Søltoft, Ulrich Jäger & Anders Österborg. (2017) Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia. Annals of Hematology 96:10, pages 1681-1691.
Crossref
Sonja Sorensen, Mark Wildgust, Nishan Sengupta, Cristina Trambitas, Joris Diels, Suzy van Sanden, Yingxin Xu & Emily Dorman. (2017) Indirect Treatment Comparisons of Ibrutinib Versus Physician?s Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia. Clinical Therapeutics 39:1, pages 178-189.e5.
Crossref
Maria Winqvist, Fariba Mozaffari, Marzia Palma, Sandra Eketorp Sylvan, Lotta Hansson, Håkan Mellstedt, Anders Österborg & Jeanette Lundin. (2016) Phase I–II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints. Cancer Immunology, Immunotherapy 66:1, pages 91-102.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.